Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Zasocitinib (TAK-279) in Psoriatic Arthritis
jRCT2031260033Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of zasocitinib in psoriatic arthritis (PsA) (2 arms), sponsored by Takeda. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Number of Participants With Adverse Events of Special Interest (AESI) and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
zasocitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCT2031260033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260033.